Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB8 versus Avastin in metastatic or recurrent non-squamous NSCLC
2015-004026-34Phase 3Completed
- Sponsor
- Samsung Bioepis
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab in Non-small cell lung cancer (NS-NSCLC) (2 arms), sponsored by Samsung Bioepis. Primary endpoint: Best overall response rate by 24 weeks. Started Feb 2016; status: completed.
02
Drugs
bevacizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2015-004026-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004026-34.